We’ve Pioneered a New Category in Regenerative Medicine

Our Patents

Our discoveries are backed by 150+ U.S. and International issued/pending patents across a variety of clinical pathways, peer review papers, and years of R&D. Our studies have proven fibroblasts to be more effective and more potent than stem cells in the regeneration of tissue and reduction in inflammation.

We are changing the treatment paradigm for chronic diseases with fibroblast cell-based therapies.

159 Patents issued and pending


Want to know what’s in the Pipeline?